Mereo BioPharma (MREO) Price to Sales (2023 - 2025)
Mereo BioPharma's (MREO) quarterly Price to Sales came in at 862.31 in Q2 2025, up 166.15% quarter-over-quarter from 323.99 in Q4 2023.
Powered by 
Analysis
Mereo BioPharma (MREO) Price to Sales (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported Price to Sales for 2 consecutive years, with 862.31 the latest figure, recorded in Q2 2025.
- On a quarterly basis, Price to Sales changed N/A year-over-year to 862.31 in Q2 2025; TTM through Jun 2026 was 102.2, a 88.15% decrease from a year earlier, with the FY2025 full-year figure at 133.02, changed N/A from the prior year.
- Price to Sales was 862.31 for Q2 2025 at Mereo BioPharma, up from 323.99 in the prior quarter.
- Over five years, Price to Sales peaked at 862.31 in Q2 2025 and troughed at 18.87 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Mereo BioPharma | 38.92 Mn | 38.92 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 862.31 |
| Dec 31, 2023 | 323.99 |
| Jun 30, 2023 | 18.87 |